CAPA In-vitro Oocyte Maturation

In vitro oocyte maturation (IVM) is a mild-approach assisted reproductive technology (ART). Because of its simplicity, the more favorable financial implications (reduced cost) for patients, and the lower health risk profile of IVM compared to controlled ovarian stimulation (COS) in polycystic ovary syndrome (PCOS) patients, the use of IVM in selected patients may gain increasing interest. Besides its application in patients with polycystic ovaries, IVM technology may have a role in fertility preservation, where young girls and adult women are facing infertility due to gonadotoxic chemotherapeutic treatment.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Infertility, Female Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Infertility Urogenital Diseases

Age range

0 month–50 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Prince of Wales Hospital

Hong Kong

Location status: Recruiting

Location contact

Jacqueline Pui Wah CHUNG, MBBS

CONTACT

[email protected]

30501537

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients aged from 0-50 years old
Patients seek fertility preservation services
Patients seek oocyte retrieval services

Exclusion criteria

-Patients unable to provide consent/assent (i.e. significant psychiatric problems/cognitive delay)

Treatment and study plan

CAPA IVM

Procedure

In CAPA-IVM, the oocyte is treated and matured outside the woman's body, while in classical IVF, the patient is treated. As a consequence, patients undergoing CAPA-IVM are not confronted with the typical risks and burden of systemic ovarian stimulation.

Primary outcomes

No. of mature oocytes

Time frame: 1 week

Number of mature oocytes after IVM

Study contacts

Contact information is provided by the study sponsor or research team.

Pui Wah Jacqueline Chung

CONTACT

[email protected]

+852 3505 1537

Sponsors and collaborators

Lead sponsor

Chinese University of Hong Kong

Other

Registry information

Important dates

Study start: 2025
Primary completion: 2030
Study completion: 2032
First posted: May 22, 2025
Registry last updated: Dec 8, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting